Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Legha

Showing results (151-160 of 179) with videos related to

Pageof 18
Sort By:
Investigational New Drugs|December 28, 2005
A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanomaKarl D Lewis, John A Thompson, Jeffrey S Weber, et al.
Cancer Treatment Reports|February 1, 1984
Phase II trial of amsacrine in metastatic or locally recurrent squamous cell carcinoma from head and neck primaries: a Southwest Oncology Group studyR P Witherspoon, S S Legha, R R Reimer, et al.
Cancer|May 1, 1982
Peptichemio versus melphalan (L-PAM) in advanced breast cancerA U Buzdar, S S Legha, G R Blumenschein, et al.
Cancer|March 30, 2000
A phase II study of "decrescendo" interleukin-2 plus interferon-alpha-2a in patients with progressive metastatic melanoma after chemotherapyO Eton, A C Buzaid, A Y Bedikian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1995
Prognostic value of size of lymph node metastases in patients with cutaneous melanomaA C Buzaid, L A Tinoco, D Jendiroba, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1991
Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapyK Itoh, K Hayakawa, M A Salmeron, et al.
Cancers|February 10, 2024
Suspicious Ultrasound-Occult Non-Calcified Mammographic Masses, Asymmetries, and Architectural Distortions Are Moderate Probability for MalignancyEthan O Cohen, Rachel E Perry, Ravinder S Legha, et al.
Cancer Treatment Reviews|June 1, 1989
Interleukin-2 alone and in combination with other cytokines in melanoma: the investigational approach at the University of Texas M.D. Anderson Cancer CenterD R Parkinson, M Talpaz, K H Lee, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 12, 2001
Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years laterC F Verschraegen, M Benjapibal, W Supakarapongkul, et al.
Cancer Research|February 1, 1990
Radioimaging of melanoma using 99mTc-labeled Fab fragment reactive with a high molecular weight melanoma antigenL M Lamki, A A Zukiwski, L J Shanken, et al.
Pageof 18

Showing results (151-160 of 179) with videos related to

Sort By:
Pageof 18
Investigational New Drugs|December 28, 2005
A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanomaKarl D Lewis, John A Thompson, Jeffrey S Weber, et al.
Cancer Treatment Reports|February 1, 1984
Phase II trial of amsacrine in metastatic or locally recurrent squamous cell carcinoma from head and neck primaries: a Southwest Oncology Group studyR P Witherspoon, S S Legha, R R Reimer, et al.
Cancer|May 1, 1982
Peptichemio versus melphalan (L-PAM) in advanced breast cancerA U Buzdar, S S Legha, G R Blumenschein, et al.
Cancer|March 30, 2000
A phase II study of "decrescendo" interleukin-2 plus interferon-alpha-2a in patients with progressive metastatic melanoma after chemotherapyO Eton, A C Buzaid, A Y Bedikian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1995
Prognostic value of size of lymph node metastases in patients with cutaneous melanomaA C Buzaid, L A Tinoco, D Jendiroba, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1991
Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapyK Itoh, K Hayakawa, M A Salmeron, et al.
Cancers|February 10, 2024
Suspicious Ultrasound-Occult Non-Calcified Mammographic Masses, Asymmetries, and Architectural Distortions Are Moderate Probability for MalignancyEthan O Cohen, Rachel E Perry, Ravinder S Legha, et al.
Cancer Treatment Reviews|June 1, 1989
Interleukin-2 alone and in combination with other cytokines in melanoma: the investigational approach at the University of Texas M.D. Anderson Cancer CenterD R Parkinson, M Talpaz, K H Lee, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 12, 2001
Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years laterC F Verschraegen, M Benjapibal, W Supakarapongkul, et al.
Cancer Research|February 1, 1990
Radioimaging of melanoma using 99mTc-labeled Fab fragment reactive with a high molecular weight melanoma antigenL M Lamki, A A Zukiwski, L J Shanken, et al.
Pageof 18